CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
RCC-TEST is an in vitro diagnostic tool designed to personalize treatment for metastatic renal cell cancer patients. It utilizes 3D tumor spheroids to test the effectiveness of therapies, aiming to improve patient outcomes and reduce healthcare costs.
In oncology today, only 10 to 15% of patients respond strongly to therapeutic treatments.
Metastatic renal cell cancer (mRCC) is no exception.
It is one of the most treatment-resistant malignancies. 30% of patients are diagnosed with a metastatic disease.
In such cases, the only solution is a radical surgical resection of the tumor, followed by the necessary therapies.
About 80% of cases fail to respond to current therapeutic agents.
New protocols with combined immuno- and targeted therapies hav…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
